Research progress of P-glycoprotein induction

XU Yue; CHEN Genfu; XIONG Tao; PENG Ying; RUAN Tingting; WANG Guangji; SUN Jianguo

doi:10.11665/j.issn.1000-5048.20180104

Journal of China Pharmaceutical University > 2018 > 49(1): 26-33. > DOI: 10.11665/j.issn.1000-5048.20180104

XU Yue, CHEN Genfu, XIONG Tao, PENG Ying, RUAN Tingting, WANG Guangji, SUN Jianguo. Research progress of P-glycoprotein induction[J]. Journal of China Pharmaceutical University, 2018, 49(1): 26-33. DOI: 10.11665/j.issn.1000-5048.20180104

Citation:

PDF (1690 KB)

Research progress of P-glycoprotein induction

More Information

Graphical Abstract

Abstract

Abstract

P-glycoprotein(P-gp)is an important efflux protein of ATP-binding cassette transporter superfamily. Cells could be protected from detrimental xenobiotics by the up-regulation of efflux pumps. In this review, an extensive literature search for P-gp induction research was conducted, and a focus was brought onto the P-gp induction models, experiment methods and its applications in drug discovery. We mainly introduced the in vitro cell-based models and in vivo rodent animal models for induction research, methods that investigate induction potency by detecting the protein, gene expression and efflux function, as well as co-regulation between P-gp and other transporters or drug metabolism enzymes. P-gp induction can serve as a clinical therapeutic strategy by reducing the intracellular concentration of deleterious xenobiotics significantly, and the in silico P-gp induction pharmacophore model was also discussed. This review could be of great importance for pre-clinical drug design, the screening of new synthesized compounds and the prediction of potential clinical drug-drug interactions.
- P-glycoprotein,
- induction,
- cell model,
- antidotal effect

FullText(HTML)

References (51)

References

[1]	Silva R,Vilas-Boas V,Carmo H,et al.Modulation of P-glycoprotein efflux pump:induction and activation as a therapeutic strategy[J].Pharmacol Ther,2015,149:1-123.
[2]	Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier[J].Adv Drug Deliv Rev,1999,36(2/3):179-186.
[3]	Zhuo W,Hu L,Lv J,et al.Role of pregnane X receptor in chemotherapeutic treatment[J].Cancer Chemother Pharmacol,2014,74(2):217-227.
[4]	Hennessy M.A primer on themechanics of P-glycoprotein the multidrug transporter[J].Pharmacol Res,2007,55(1):1-15.
[5]	Weiss J,Theile D,Spalwisz A,et al.Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells[J].Biochem Pharmacol,2013,85(2):265-273.
[6]	Naruhashi K, Kurahashi Y, Fujita Y, et al. Comparison of the expression and function of ATP binding cassette transporters in Caco-2 and T84 cells on stimulation by selected endogenous compounds and xenobiotics[J].Drug Metab Pharmacok,2011,26(2):145-153.
[7]	Manceau S,Giraud C,Declèves X,et al.ABC drug transporter and nuclear receptor expression in human cytotrophoblasts:influence of spontaneous syncytialization and induction by glucocorticoids[J].Placenta,2012,33(11):927-932.
[8]	Haslam IS,Jones K,Coleman T,et al.Induction of P-glycoprotein expression and function in human intestinal epithelial cells(T84)[J].Biochem Pharmacol,2008,76(7):850-861.
[9]	Abuznait AH,Kaddoumi A.Role of ABC transporters in the pathogenesis of Alzheimer′s disease[J].ACS Chem Neurosci,2012,3(11):820-831.
[10]	He J, Tang J, Yang WH, et al. P-gp induction by curcumin:an effective antidotal pathway[J].J Bioequiv Bioavail, 2013,5(6):236-241.
[11]	Sérée E,Villard PH,Hevér A.Modulation of MDR1 and CYP3A expression by dexamethasone:evidence for an inverse regulation in adrenals[J].Biochem Biophys Res Commun,1998,252(2):392-395.
[12]	Wen T,Liu YC,Yang HW,et al.Effect of 21-day exposure of phenobarbital,carbamazepine and phenytoin on P-glycoprotein expression and activity in the rat brain[J].J Neurol Sci,2008,271(1):99-106.
[13]	Foti RS.“Target-Site” drug metabolism and transport[J].Drug Metab Dispos,2015,43(8):1156-1168.
[14]	Müller F,Fromm MF.Transporter-mediated drug-drug interactions[J].Pharmacogenomics,2011,12(7):7-21.
[15]	Synold TW,Dussault I,Forman BM.The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux[J].Nat Med,2001,7(5):584-590.
[16]	Liu L,Collier AC,Link JM,et al.Modulation of P-glycoprotein at the human blood-brain barrier by quinidine or rifampin treatment:a positron emission tomography imaging study[J].Drug Metab Dispos,2015,43(11):1795-1804.
[17]	Sager JE,Yu J,Ragueneau-Majlessi I,et al.Physiologically based pharmacokinetic(PBPK)modeling and simulation approaches:a systematic review of published models,applications,and model verification[J].Drug Metab Dispos,2015,43(11):1823-1837.
[18]	Silva R,Carmo H,Dinis-Oliveira R,et al.In vitro study of P-glycoprotein induction as an antidotal pathway to prevent cytotoxicity in Caco-2 cells[J].Arch Toxicol,2011,85(4):315-326.
[19]	Silva R,Carmo H,Vilas-Boas V,et al.Colchicine effect on P-glycoprotein expression and activity:in silico and in vitro studies[J].Chem Biol Interact,2014,218:50-62.
[20]	Zerin T,Kim YS,Hong SY,et al.Protective effect of methylprednisolone on paraquat-induced A549 cell cytotoxicity via induction of efflux transporter,P-glycoprotein expression[J].Toxicol Lett,2012,208(2):101-107.
[21]	Silva R.Pglycoprotein induction in Caco 2 cells by newly synthetized thioxanthones prevents paraquat cytotoxicity[J].Arch Toxicol 2015,89:18.
[22]	Silva R,Sousa E,Carmo H,et al.Induction and activation of P-glycoprotein by dihydroxylated xanthones protect against the cytotoxicity of the P-glycoprotein substrate paraquat[J].Arch Toxicol,2014,88(4):937-951.
[23]	Fenner KS,Troutman MD,Kempshall S,et al.Drug-drug interactions mediated through P-glycoprotein:clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug[J].Clin Pharmacol Ther,2009,85(2):173-181.
[24]	Reitman ML,Chu X,Cai X,et al.Rifampin′s acute inhibitory and chronic inductive drug interactions:experimental and model-based approaches to drug-drug interaction trial design[J].Clin Pharmacol Ther,2011,89(2):234-242.
[25]	Fromm MF.Importance of P-glycoprotein at blood-tissue barriers[J].Trends Pharmacol Sci,2004,25(8):423-429.
[26]	Schwarz UI,Hanso H,Oertel R,et al.Induction of intestinal P-glycoprotein by St John′s wort reduces the oral bioavailability of talinolol[J].Clin Pharmacol Ther,2007,81(5):669-678.
[27]	Liu J,Zhou F,Chen Q,et al.Chronic inflammation up-regulates P-gp in peripheral mononuclear blood cells via the STAT3/Nf-kappab pathway in 2,4,6-trinitrobenzene sulfonic acid-induced colitis mice[J].Sci Rep,2015,5:13558.
[28]	Wen T,Liu YC,Yang HW,et al.Effect of 21-day exposure of phenobarbital,carbamazepine and phenytoin on P-glycoprotein expression and activity in the rat brain[J].J Neurol Sci,2008,270(1):99-106.
[29]	Jin S,Yao D,Liu C,et al.Effect of chronic liver failure on the function and expression of P-GP and MRP2 in rat brain[J].J China Pharm Univ(中国药科大学学报),2012,43(1):64-69.
[30]	Callaghan R,Luk F,Bebawy M.Inhibition of the multidrug resistance P-glycoprotein:time for a change of strategy[J]?Drug Metab Dispos,2014,42(4):623-631.
[31]	Albermann N, Schmitz-Winnenthal FH, Z′graggen K, et al.Expression of the drug transporters MDR1/ABCB1,MRP1/ABCC1,MRP2/ABCC2,BCRP/ABCG2,and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver[J].Biochem Pharmacol,2005,70(6):949-958.
[32]	Narang VS,Fraga C,Kumar N.Dexamethasone increases expresb>(4):694-705.
[33]	FDA. Guidance for industry, drug interaction studies-study design,data analysis,and implications for dosing and labeling recommendations[S].2012.J,Fuksa L,Brcakova E,et al.Up-regulation of renal Mdr1 and Mrp2 transporters during amiodarone pretreatment in rats[J].Pharmacol Res,2010,61(2):129-135.
[34]	Safa AR.Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators[J].Curr Med Chem Anticancer Agents,2004,4(1):1-17.
[35]	Aller SG, Yu J, Ward A.Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding[J].Science,2009,323(5922):1718-1722.
[36]	Drescher S,Glaeser H,Mürdter T,et al.P-glycoprotein mediated intestinal and biliary digoxin transport in humans[J].Clin Pharmacol Ther,2003,73(3):223-231.
[37]	Greiner B,Eichelbaum M,Fritz P,et al.The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin[J].J Clin Invest,1999,104(2):147-153.
[38]	Gurley BJ,Swain A,Williams DK,et al.Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions:comparative effects of St.John′s wort,Echinacea,clarithromycin,and rifampin on digoxin pharmacokinetics[J].Mol Nutr Food Res,2008,52(7):772-779.
[39]	Montanari F,Ecker GF.Prediction of drug-ABC-transporter interaction-Recent advances and future challenges[J].Adv Drug Deliv Rev,2015,86:17-26.
[40]	Westphal K,Weinbrenner A,Zschiesche M,et al.Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings:a new type of drug-drug interaction[J].Clin Pharmacol Ther,2000,68(4):345-355.
[41]	Schwarz UI,Hanso H,Oertel R.Induction of intestinal P-glycoprotein by St John′s wort reduces the oral bioavailability of talinolol[J].Clin Pharmacol Ther,2007,81(5):669-678.
[42]	Silva R.Induction and activation of P-glycoprotein by dihydroxylated xanthones protect against the cytotoxicity of the P-glycoprotein[J].Arch Toxicol,2014,88(4):15.
[43]	Silva R,Palmeira A,Carmo H,et al.P-glycoprotein induction in Caco-2 cells by newly synthetized thioxanthones prevents paraquat cytotoxicity[J].Arch Toxicol,2015,89(10):1783-1800.
[44]	Dinis-Oliveira RJ, Remiao F, Duarte JA, et al. P-glycoprotein induction:an antidotal pathway for paraquat-induced lung toxicity[J].Free Radic Biol Med,2006,41(8):1213-1224.
[45]	Murgueitio MS,Bermudez M,Mortier J,et al.In silico virtual screening approaches for anti-viral drug discovery[J].Drug Discovery Today:Technologies,2012,9(3):e219-e225.
[46]	Lu JR,Wang FX,Li YM,et al.Synthesis,biological evaluation and 2D-QSAR study of a series of isoflavone derivatives as modulators of multidrug resistance[J].J China Pharm Univ(中国药科大学学报),2013,44(4):296-302.
[47]	Padala AK,Wani A,Vishwakarma RA,et al.Functional induction of P-glycoprotein efflux pump by phenyl benzenesulfonamides:synthesis and biological evaluation of T0901317 analogs[J].Eur J Med Chem,2016,122:744-755.
[48]	Vilas-Boas V,Silva R,Palmeira A.Development of novel rifampicin-derived P-glycoprotein activators/inducers.Synthesis,in silico analysis and application in the RBE4 cell model,using paraquat as substrate[J].PLoS One,2013,8(8):e74425.
[49]	Yamaura Y,Chapron BD,Wang Z,et al.Functional comparison of human colonic carcinoma cell lines and primary small intestinal epithelial cells for investigations of intestinal drug permeability and first-pass metabolism[J].Drug Metab Dispos,2016,44(3):329-335.
[50]	Bourgine J,Billaut-Laden I,Happillon M,et al.Gene expression profiling of systems involved in the metabolism and the disposition of xenobiotics:comparison between human intestinal biopsy samples and colon cell lines[J].Drug Metab Dispos,2012,40(4):694-705.
[51]	FDA. Guidance for industry, drug interaction studies-study design,data analysis,and implications for dosing and labeling recommendations[S].2012.

[1]	LI Zhi, LI Meng, SUN Hao, LIU Dongfei. Progress in lipid emulsions as antidotes to reverse drug poisoning[J]. Journal of China Pharmaceutical University, 2022, 53(3): 348-355. DOI: 10.11665/j.issn.1000-5048.20220313
[2]	ZHANG Xue, OUYANG Huizhi, XU Wei, WANG Xiaoying. Effect of celastrol combined medication on the inhibition of HepG2 cell proliferation[J]. Journal of China Pharmaceutical University, 2020, 51(2): 185-192. DOI: 10.11665/j.issn.1000-5048.20200209
[3]	WU Yanqing, CAO Qingqing, ZHANG Ting, ZHAI Yu, LI Wenping, YANG Jin. Effects of clinical P-glycoprotein inhibitors on oral bioavailability and brain penetration of gefitinib[J]. Journal of China Pharmaceutical University, 2019, 50(2): 206-212. DOI: 10.11665/j.issn.1000-5048.20190212
[4]	DAI Huiteng, TIAN Hong, HUANG Jie, CHEN Chao, CAI Di, GAO Xiangdong, YAO Wenbing. Protective effects of p-nitrophenylalanine-containing BAFF vaccine on lupus nephritis model mice[J]. Journal of China Pharmaceutical University, 2017, 48(4): 483-489. DOI: 10.11665/j.issn.1000-5048.20170414
[5]	LIU Zhi-yong, NIU Zhi-yuan, ZHENG Wei, SHEN Ping-ping. Effects of p-ERK1/2 on nitric oxide donor induced apoptosis of HepG2 cells[J]. Journal of China Pharmaceutical University, 2012, 43(6): 530-534.
[6]	Studies on Inhibitive Effect of Gastrodin on PC12 Cell Damage Induced by Glutamate and H2O2[J]. Journal of China Pharmaceutical University, 2003, (5): 70-74.
[7]	Effect of Lomerizine on Multidrug Resistance in Human Leukemic Cell Line K562/A02[J]. Journal of China Pharmaceutical University, 2003, (4): 70-74.
[8]	Effect of Lomerizine on the Activity of P-glycoprotein in Primary Cultured Rat Brain Microvessel Endothelial Cells[J]. Journal of China Pharmaceutical University, 2003, (4): 62-65.
[9]	Anti-oxidative Activity ofHuanglian Jiedu Tang, a Traditional Chinese Recipe[J]. Journal of China Pharmaceutical University, 2001, (1): 53-55.
[10]	Enhancing Effect of Geraniol on the Permeation of 5 Fluorouracil Through Excised Rat Skin[J]. Journal of China Pharmaceutical University, 1997, (4): 16-19.

Cited By

Get Citation

PDF

XML

Article views (1669) PDF downloads (2171)

Turn off MathJax

Article Contents

Abstract

References

Research progress of P-glycoprotein induction

Abstract

References

Related Articles

Catalog

Research progress of P-glycoprotein induction

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content